The nation of Zimbabwe has rejected a significant US health deal worth 367 million US dollars (£272m) spanning five years due to the United States' demand for confidential biological samples.
This move came to light after a government memo from December was leaked, indicating that Head of State Emmerson Mnangagwa deemed the agreement was "lopsided".
A government representative later stated that the US was requesting health data for research and commercial purposes while was unwilling to guarantee the resulting advantages from future vaccines.
"We are forced to start the difficult and regrettable task of scaling back our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the US had donated more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged further dialogue to secure a agreement suitable to both sides so the nation's vital HIV programme can continue.
Wider Context
Zimbabwe's decision comes after a similar situation in Kenya, where a court blocked a similar deal with the US after concerns were raised about the safety of Kenyans' medical information.
After returning to the presidency last year, US President Donald Trump has drastically cut foreign aid and closed the US Agency for International Development (USAID).
The agency had administered assistance for the American government, but Trump claimed its expenditure was "wasteful" and his government was pursuing direct bilateral deals to boost openness and responsibility.
As per reports, Sixteen nations in Africa have to date agreed to these new health pacts, representing over $18.3bn in committed funds.
Details of the Declined Agreement
The money for Zimbabwe would have gone towards "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this collaboration would have delivered immense benefits for Zimbabwean communities, particularly the 1.2 million men, women and children currently receiving HIV treatment via American-funded initiatives," Tremont commented.
However, government spokesperson Nick Mangwana said the arrangement was "asymmetrical".
"Our nation was requested to provide its biological resources and data for a long time, without any corresponding assurance of access to any medical innovations – such as new medicines or tests – that might result from that shared data," his statement read.
"Effectively, our country would provide the basic resources for scientific discovery without any assurance that the end products would be available to our people should a future pandemic emerge."
Sovereignty and Global Health
Mangwana further noted that the American exit from the global health body and its pursuit of bilateral health agreements were disrupting systems previously established via the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing framework created to manage future pandemics.
"This system is intended to guarantee that when a nation contributes its samples, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised solely by those with the resources to create them."
These objections over the US deal "are not meant as opposition to America," Mangwana stressed.
"We are open to further discussions with our US partners on how subsequent co-operation could be arranged in a way that respects the independence and interests of both nations."
Medical Community Reaction
Medical experts expressed it acknowledged the official position, but recommended that talks must proceed given that a large portion of the nation's HIV programmes were funded by foreign aid.
"In cases where technical issues arise, including those relating to information security or implementation frameworks, these can often be addressed via detailed discussion and mutually agreed protections," it said.
The situation emphasises the ongoing debate between accepting much-needed foreign assistance and protecting local interests in an ever more data-driven world.